 Source: PanuwachShutterstock Sarepta Therapeutics NASDAQ: SRPT stock is rising higher on Friday thanks to an update concerning its Duchenne muscular dystrophy treatment. According to the company, it plans to seek a Biologics License Application BLA for accelerated approval of SRP-9001 from the U.S. Food and Drug Administration FDA. 